Compare OSPN & HELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OSPN | HELP |
|---|---|---|
| Founded | 1991 | 2019 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 946.7M | 862.2M |
| IPO Year | 2000 | 2020 |
| Metric | OSPN | HELP |
|---|---|---|
| Price | $22.22 | $8.94 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 11 |
| Target Price | $23.50 | ★ $41.56 |
| AVG Volume (30 Days) | 888.5K | ★ 1.4M |
| Earning Date | 10-29-2026 | 11-24-2026 |
| Dividend Yield | ★ 2.32% | N/A |
| EPS Growth | ★ 28.77 | N/A |
| EPS | ★ 0.68 | N/A |
| Revenue | ★ $243,180,000.00 | N/A |
| Revenue This Year | $5.28 | N/A |
| Revenue Next Year | $2.44 | N/A |
| P/E Ratio | $33.17 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.07 | $3.76 |
| 52 Week High | $27.45 | $15.15 |
| Indicator | OSPN | HELP |
|---|---|---|
| Relative Strength Index (RSI) | 56.84 | 40.70 |
| Support Level | $21.29 | $4.41 |
| Resistance Level | $27.45 | $11.74 |
| Average True Range (ATR) | 1.24 | 0.80 |
| MACD | -0.14 | -0.00 |
| Stochastic Oscillator | 37.47 | 26.77 |
OneSpan Inc is a provider of information technology security solutions for banking and financial services and application security markets. The company build secure, seamless, and trusted digital experiences through two solution portfolios: Cybersecurity solutions engaged in protecting identities, securing mobile apps, and safeguarding access through high-assurance authentication, threat intelligence, fraud prevention, and robust mobile app protection, defending users, devices, and applications against sophisticated attacks, while Digital agreement solutions focuses on streamlining workflows with secure e-signatures, identity verification, and smart digital forms, built to enable speed, compliance and other customer experiences.
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.